BiVictriX Therapeutics plc announced that Non-Executive Director, Iain Ross, is stepping down from the board with immediate effect to pursue other interests. A Nomination Committee, consisting of Non-Executive Directors and chaired by Dr. Michael Kauffman, will initiate a search for Iain's replacement with appropriate skills to help move the Company forward, in anticipation of its first clinical trials in patients with Acute Myeloid Leukaemia.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.5 GBX | 0.00% | 0.00% | +9.52% |
Apr. 17 | Bivictrix granted FDA orphan drug status for rare cancer treatment | AN |
Apr. 17 | BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.52% | 11.89M | |
-0.27% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.44% | 24.63B | |
-23.96% | 18.2B | |
+26.79% | 12.01B | |
-3.21% | 11.76B | |
+13.38% | 10.4B | |
-3.51% | 9.94B |
- Stock Market
- Equities
- BVX Stock
- News BiVictriX Therapeutics Plc
- Bivictrix Therapeutics plc Announces Resignation of Iain Ross from the Board